Cognition Therapeutics Crecimiento futuro
Future controles de criterios 0/6
Se prevé que los beneficios de Cognition Therapeutics disminuyan a un ritmo anual de 30.4%, mientras que sus ingresos anuales crecerán a un ritmo de 64.7% por año. Se espera que el BPA disminuya en un 6.6% al año.
Información clave
-30.4%
Tasa de crecimiento de los beneficios
-6.62%
Tasa de crecimiento del BPA
| Crecimiento de los beneficios de Pharmaceuticals | 14.4% |
| Tasa de crecimiento de los ingresos | 64.7% |
| Rentabilidad financiera futura | n/a |
| Cobertura de analistas | Low |
| Última actualización | 18 May 2026 |
Actualizaciones recientes sobre el crecimiento futuro
Recent updates
Here's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
DLB Psychosis Program And Biomarker Strategy Will Shape Long Term Upside Potential
Catalysts About Cognition Therapeutics Cognition Therapeutics is a clinical stage biopharmaceutical company focused on developing zervimesine for neurodegenerative diseases such as dementia with Lewy bodies and Alzheimer's disease. What are the underlying business or industry changes driving this perspective?We're Keeping An Eye On Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, Cognition...We're A Little Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Will Have To Spend Its Cash Wisely
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Can Cognition Therapeutics (NASDAQ:CGTX) Afford To Invest In Growth?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition Therapeutics: Shines Less Bright After Phase 2 Results In Alzheimer's Disease
Summary Cognition Therapeutics' stock dropped over 40% after Phase 2 trial results for Alzheimer's disease. Results showed cognitive benefit but fading statistical significance over time. CT1812 did not outperform placebo on all rating scales over 3-6 months, raising concerns for future milestones and larger trials. Financial reliance on NIH grants poses risks, and ongoing trials in dementia with Lewy Bodies, Alzheimer's and dry AMD have the potential for further stock decline. Read the full article on Seeking AlphaIs Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Cognition Therapeutics: Approaching Phase 2 Readout In Alzheimer's
Summary Cognition Therapeutics is set to report topline data from its Phase 2 trial in Alzheimer's disease in mid-2024. CT1812, the company's lead drug candidate, is a sigma-2 receptor antagonist for Alzheimer's and aims to prevent the binding of toxic Aβ oligomers. Preliminary data from the ongoing SHINE trial showed some interesting results, but were not consistent with other previous studies, raising caution about the upcoming data. At a ~$70 million market cap with about half of that cash, the topline readout could be a binary event for the stock. Read the full article on Seeking AlphaHere's Why We're Watching Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Situation
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...Is Cognition Therapeutics (NASDAQ:CGTX) In A Good Position To Deliver On Growth Plans?
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition Therapeutics (NASDAQ:CGTX) Is In A Good Position To Deliver On Growth Plans
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Cognition stock rises 12% on $2.14M grant from NIH for Alzheimer's study
Cognition Therapeutics (NASDAQ:CGTX) said it received a $2.14M grant from the National Institute on Aging (NIA) to help complete an ongoing study of CT1812 in adults with mild-to-moderate Alzheimer's disease. The study called SEQUEL will evaluate if CT1812 results in a normalization of the EEG patterns. The trial is enrolling 16 adults who will receive either CT1812 or placebo, the company said in a Sept. 27 press release. Cognition noted that the study is taking place at the Amsterdam UMC Dept. of Neurology/Alzheimer Center and Brain Research Center. The NIA, a division of the National Institutes of Health (NIH), awarded a $3.2M grant in 2020 to support the study and has now awarded $2.14M, the company added. CGTX +12.28% to $1.92 premarket Sept. 27We Think Cognition Therapeutics (NASDAQ:CGTX) Can Afford To Drive Business Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Cognition's Alzheimer's candidate demonstrates mechanism of action; shares soar
An analysis of biomarker data from Cognition Therapeutics' (NASDAQ:CGTX) Alzheimer's disease candidate CT1812 indicate the oral once-daily treatment supports a synaptoprotective mechanism of action and has a role in normalizing cellular processes. Proteomic analyses demonstrated CT1812's impact on several Alzheimer's biomarkers, including YKL-40, which is an indicator of inflammation and is upregulated in the disease. Results showed that participants given CT-1812 saw declining levels of YKL-40. The candidate also had a significant impact on cerebrospinal fluid levels of clusterin, a genetic risk factor for Alzheimer's. Cognition closed up 62% on Thursday but is down 16% in Friday premarket trading.We're Not Very Worried About Cognition Therapeutics' (NASDAQ:CGTX) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Previsiones de crecimiento de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Flujo de caja libre | Flujo de caja operativo | Núm. de analistas medio |
|---|---|---|---|---|---|
| 12/31/2028 | N/A | -103 | -91 | N/A | 1 |
| 12/31/2027 | N/A | -34 | -64 | N/A | 3 |
| 12/31/2026 | N/A | -32 | -58 | N/A | 4 |
| 3/31/2026 | N/A | -20 | N/A | N/A | N/A |
| 12/31/2025 | N/A | -23 | -25 | -25 | N/A |
| 9/30/2025 | N/A | -28 | -30 | -30 | N/A |
| 6/30/2025 | N/A | -33 | -31 | -31 | N/A |
| 3/31/2025 | N/A | -33 | -31 | -31 | N/A |
| 12/31/2024 | N/A | -34 | -28 | -28 | N/A |
| 9/30/2024 | N/A | -34 | -26 | -26 | N/A |
| 6/30/2024 | N/A | -31 | -23 | -23 | N/A |
| 3/31/2024 | N/A | -29 | -21 | -21 | N/A |
| 12/31/2023 | N/A | -26 | -16 | -16 | N/A |
| 9/30/2023 | N/A | -23 | -21 | -21 | N/A |
| 6/30/2023 | N/A | -23 | -17 | -17 | N/A |
| 3/31/2023 | N/A | -24 | -18 | -18 | N/A |
| 12/31/2022 | N/A | -21 | -19 | -19 | N/A |
| 9/30/2022 | N/A | -24 | -8 | -8 | N/A |
| 6/30/2022 | N/A | -22 | -10 | -10 | N/A |
| 3/31/2022 | N/A | -19 | -6 | -6 | N/A |
| 12/31/2021 | N/A | -16 | -4 | -4 | N/A |
| 9/30/2021 | N/A | -12 | -4 | -4 | N/A |
| 6/30/2021 | N/A | -10 | -3 | -3 | N/A |
| 3/31/2021 | N/A | -9 | -5 | -5 | N/A |
| 12/31/2020 | N/A | -12 | -3 | -3 | N/A |
Previsiones de crecimiento futuro de los analistas
Ingresos vs. Tasa de ahorro: Se prevé que CGTX siga sin ser rentable en los próximos 3 años.
Beneficios vs. Mercado: Se prevé que CGTX siga sin ser rentable en los próximos 3 años.
Beneficios de alto crecimiento: Se prevé que CGTX siga sin ser rentable en los próximos 3 años.
Ingresos vs. Mercado: Se prevé que CGTX no tenga ingresos el año que viene.
Ingresos de alto crecimiento: Se prevé que CGTX no tenga ingresos el año que viene.
Previsiones de crecimiento de los beneficios por acción
Rentabilidad financiera futura
ROE futura: Datos insuficientes para determinar si la rentabilidad financiera de CGTX se prevé que sea elevada dentro de 3 años.
Descubre empresas en crecimiento
Análisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/05/20 15:46 |
| Precio de las acciones al final del día | 2026/05/20 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Cognition Therapeutics, Inc. está cubierta por 7 analistas. 4 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| William Wood | B. Riley Securities, Inc. |
| Mayank Mamtani | B. Riley Securities, Inc. |
| null null | B. Riley Securities, Inc. |